Axsome Therapeutics heads into its August 3 earnings print with the most significant development since last week's note being a sharp reversal in short positioning — a story that materially changes the setup described just days ago.
The headline shift is in short interest, which has fallen nearly 20% over the past week to 5.2% of the free float. That drop — from around 3.26 million shares short to 2.62 million — erases most of the rebuilding that defined the previous note's narrative. The unwind happened in a single step: shorts cut exposure sharply between July 8 and July 10, then held near those lower levels through the rest of the week. The borrow market reflects no stress on either side. Availability is essentially unlimited — over 51 million shares remain available to lend against a short position of just 2.6 million — and cost to borrow runs at a negligible 0.42%, barely changed on the week. The ORTEX short score has dropped in parallel, falling from roughly 44 at the start of July to 39.6 today, moving away from territory that would signal meaningful bearish conviction. Positioning looks far less contested than it did a week ago.
Options traders have also rotated away from downside protection. The put/call ratio has dropped to 0.80, nearly two standard deviations below its 20-day average of 0.88 — a reading that reflects more call-side interest than has been typical for months. As recently as early June, the PCR was running above 1.0; the current reading is close to the 52-week low of 0.48. That combination of short covering and a call-skewed options book paints an increasingly constructive near-term setup heading into earnings.
The Street remains broadly bullish, and the analyst picture has not materially changed since the July 8 note. RBC Capital holds an Outperform with a $304 target. TD Cowen and HC Wainwright are both at Buy with targets of $300 and $290 respectively. The consensus mean target is $280, about 19% above the current price of $235.26 — which has pulled back roughly 6% on the week and 8% over the past month, leaving the stock sitting below several analyst targets. Morgan Stanley is the lone significant holdout at Equal-Weight with a $242 target, itself now above spot. EPS momentum remains exceptional, ranking in the 96th percentile on both 30- and 90-day measures. The bull case centres on Auvelity prescription growth and pipeline depth in CNS disorders. Bears continue to focus on execution risk around AXS-12's late 2026 regulatory timeline and competition in the narcolepsy space.
The insider picture adds some caution. CEO Herriot Tabuteau sold nearly 50,000 shares on July 1 for approximately $11.9 million, following an almost identical sale on June 9. CFO Nick Pizzie also sold 33,000 shares in early June for around $7.9 million. The 90-day net insider position is nominally positive at roughly 164,000 shares, but that reflects awards rather than open-market buying — all the cash transactions on record are sales. Institutional holders are broadly stable, with BlackRock and Fidelity adding modestly in the most recent quarter and Antecip Capital holding its dominant 14.3% stake unchanged.
The August 3 print is the next hard catalyst. The stock has risen an average of 8% on the day of the two most recent earnings releases, with gains extending further over the subsequent week. Whether the combination of a lighter short base, call-heavy options positioning, and a stock now trading 8% below its recent highs translates into a repeat of that pattern is the question the market will be answering over the next three weeks.
See the live data behind this article on ORTEX.
Open AXSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
